Regenxbio Inc (NAS:RGNX) Stock News, Headlines & Updates
Regenxbio Inc Stock News from GuruFocus
- 1
Jun 29, 2026
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
PRNewswire • 7:00am
8-K - REGENXBIO Inc. (0001590877)
Gurufocus News • 7:00pm
Jun 24, 2026
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026
PRNewswire • 7:00am
Regenxbio (RGNX) Advances Gene Therapy for Duchenne Muscular Dystrophy
Gurufocus News • 6:28am
Jun 22, 2026
Regenxbio (RGNX) Receives FDA Alignment for Navsunli Resubmission
Gurufocus News • 9:25am
Regenxbio (RGNX) Secures FDA Pathway for Navsunli Accelerated Approval
Gurufocus News • 7:29am
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLIâ„¢ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
PRNewswire • 7:00am
Regenxbio (RGNX) Stock Surges Following FDA Decision on Gene Therapy
Gurufocus News • 6:26am
Jun 06, 2026
JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc.
Gurufocus News • 8:24pm
- 1
Show
Entries
Headlines
Total 0- 1
No recent news